z-logo
Premium
Influence of plerixafor on the mobilization of CD34+ cell subpopulations and lymphocyte subtypes
Author(s) -
Worel Nina,
Frank Nelli,
Frech Christian,
Fritsch Gerhard
Publication year - 2017
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/trf.14182
Subject(s) - plerixafor , cd34 , apheresis , cd38 , immunology , progenitor cell , lymphocyte , granulocyte colony stimulating factor , leukapheresis , haematopoiesis , medicine , stem cell , andrology , cancer research , chemotherapy , oncology , biology , cxcr4 , chemokine , platelet , immune system , microbiology and biotechnology
BACKGROUND Peripheral blood stem cells mobilized with granulocyte–colony‐stimulating factor (G‐CSF) with or without chemotherapy are routinely used for autologous hematopoietic cell transplantation. Plerixafor, a chemokine‐receptor inhibitor, increases the amount of circulating CD34+ cells and improves harvest results. However, limited information is available regarding the composition of apheresis products with respect to CD34+ and lymphocyte subtypes collected after various mobilization regimens. STUDY DESIGN AND METHODS We used a recently established single‐platform multicolor flow‐cytometric analysis including CD45RA and CD133 to define CD34+ subpopulations and lymphocyte subsets in products obtained either after G‐CSF with or without chemotherapy alone (G, n = 40) or with addition of plerixafor (GP, n = 40). RESULTS Absolute numbers of white blood cells and lymphocyte subtypes were significantly higher after plerixafor, which was not observed for absolute CD34+ counts. However, distinct differences in terms of CD34+ subtypes were observed. The most primitive multipotent progenitors (CD45RA–CD133+CD34+CD38 low ) predominated significantly after G (median, 49.2%; range, 15.2%‐63%) compared to GP (median, 34.4%; range, 12%‐62%; p < 0.001), whereas more differentiated subsets clearly prevailed after GP. CONCLUSION In contrast to the findings of other authors, our study shows a clear shift toward more committed CD34+ subsets after plerixafor in poor mobilizers and elucidates the importance of informative surface markers like CD45RA and CD133 in addition to CD38 to discriminate earlier from more committed CD34+ cells. Further studies are needed to analyze whether these findings have an impact on clinical outcome.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here